Gland Pharma Q4 Profit Doubles on US Strength, Declares ₹20 Dividend

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSatyam Jha|Published at:
Gland Pharma Q4 Profit Doubles on US Strength, Declares ₹20 Dividend
Overview

Gland Pharma reported a stellar fourth quarter, with net profit nearly doubling to ₹366.6 crore. Revenue climbed 22.3% year-on-year, boosted by robust performance in its US business and strong growth in the CDMO segment. The company also announced a final dividend of ₹20 per share.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Profit Surge Fueled by US Market and CDMO Expansion

Gland Pharma Ltd. posted a robust fourth quarter for fiscal year 2026, announcing a consolidated net profit of ₹366.6 crore. This represents a significant 96.6% year-on-year increase, driven by substantial revenue growth and improved operating performance.

Revenue for the quarter jumped 22.3% to ₹1,742.7 crore, a stark rise from ₹1,424.9 crore in the same period last year. This expansion was largely attributed to successful new product launches in the United States and a burgeoning Contract Development and Manufacturing Organization (CDMO) business. The CDMO segment contributed 46% of revenues, experiencing a 36% year-on-year growth in Q4 FY26.

Strong Operating Metrics and Pipeline Development

EBITDA saw a considerable 47.6% surge to ₹512.9 crore, expanding the EBITDA margin to 29.4% from 24.4% a year prior. Adjusted Profit After Tax (PAT) similarly jumped 97% year-on-year. Gland Pharma maintained its focus on research and development, investing ₹50.6 crore in Q4 FY26 for complex product development and filings. The company also noted progress in its complex pipeline and co-development partnerships, anticipating future growth from these areas.

Dividend Payout and Market Reaction

Reflecting its strong financial performance, the board recommended a final dividend of ₹20 per equity share for FY26. This shareholder-friendly move comes despite the company's shares closing down 1.80% at ₹1,861.00 on the BSE. The company launched five new molecules in the US during the quarter, contributing to a total of 31 US launches for FY26, bolstering its market presence and future revenue streams.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.